Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.astecls.com | |
Market Cap | 2,575.47 Cr. | |
Enterprise Value(EV) | 2,914.50 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 3.04 | Trailing Twelve Months Ending 2023-06 |
Price-Earning Ratio (PE) | 429.74 | Trailing Twelve Months Ending 2023-06 |
Industry PE | 26.47 | Trailing Twelve Months Ending 2023-06 |
Book Value / Share | 209.54 | Trailing Twelve Months Ending 2023-06 |
Price to Book Value | 6.24 | Calculated using Price: 1,308.35 |
Dividend Yield | 0.11 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.96 Cr. | 19,609,206 Shares |
FaceValue | 10 | |
About Astec Lifesciences Ltd. | ||
Astec is proud of its rich experience of over two decades in the chemical industry. The company employs highly qualified and trained personnel to monitor and maintain its manufacturing activities as well as process development work. Astec prides itself in being responsive, reliable and quick to implement projects. A strong R&D focus has enabled the company to introduce a number of unique products. As the operations are highly integrated both vertically and horizontally, Astec has a very efficient, low cost structure in the market place. |
1 Day |
|
-2.80% |
1 Week |
|
-4.87% |
1 Month |
|
-2.55% |
3 Month |
|
-3.45% |
6 Month |
|
+7.93% |
1 Year |
|
-30.93% |
2 Year |
|
-1.24% |
5 Year |
|
+134.11% |
10 Year |
|
+5551.62% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 11.88 | 4.01 | 15.07 | 22.90 | 19.31 | 21.24 | 23.46 | 25.50 | 6.28 | |
Return on Capital Employed (%) | 11.96 | 10.65 | 16.08 | 23.75 | 20.31 | 20.44 | 22.29 | 22.21 | 7.75 | |
Return on Assets (%) | 4.57 | 1.47 | 5.80 | 9.38 | 8.18 | 9.20 | 10.42 | 11.21 | 2.69 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Shh. Funds | 113 | 135 | 118 | 138 | 170 | 202 | 247 | 309 | 397 | 419 | |
Non Curr. Liab. | 54 | 49 | 6 | 2 | 5 | 9 | 6 | 46 | 38 | 34 | |
Curr. Liab. | 117 | 178 | 203 | 194 | 238 | 249 | 318 | 322 | 491 | 526 | |
Minority Int. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Equity & Liab. | 284 | 362 | 328 | 334 | 413 | 461 | 572 | 678 | 925 | 979 | |
Non Curr. Assets | 150 | 158 | 136 | 135 | 182 | 213 | 240 | 347 | 410 | 481 | |
Curr. Assets | 135 | 204 | 191 | 198 | 232 | 248 | 332 | 330 | 516 | 499 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 284 | 362 | 328 | 334 | 413 | 461 | 572 | 678 | 925 | 979 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
Net Sales | 267 | 247 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 587 | |
Other Income | 1 | 7 | 3 | 8 | 11 | 12 | 8 | 10 | 13 | 12 | |
Total Income | 268 | 254 | 302 | 376 | 442 | 535 | 563 | 687 | 641 | 599 | |
Total Expenditure | -213 | -215 | -236 | -299 | -354 | -437 | -443 | -522 | -552 | -533 | |
PBIDT | 55 | 39 | 65 | 77 | 88 | 97 | 119 | 165 | 89 | 66 | |
Interest | -13 | -13 | -12 | -11 | -12 | -13 | -5 | -9 | -21 | -23 | |
Depreciation | -13 | -10 | -14 | -15 | -19 | -23 | -26 | -34 | -34 | -34 | |
Taxation | 2 | -7 | -10 | -21 | -20 | -14 | -24 | -31 | -9 | -3 | |
Exceptional Items | -17 | -3 | -11 | 4 | |||||||
PAT | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | 6 | |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | 6 | |
Adjusted EPS | 8 | 3 | 10 | 18 | 18 | 24 | 33 | 46 | 13 | 3 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 15 | 7 | -13 | 19 | 65 | 15 | 168 | -8 | 24 | 75 | |
Cash Fr. Inv. | -19 | -19 | -16 | -18 | -49 | -53 | -74 | -73 | -104 | -113 | |
Cash Fr. Finan. | 3 | 12 | 31 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | |
Net Change | -1 | 0 | 2 | 1 | -3 | 0 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 4 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 0 |
Tue, 29 Aug 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Intimation under Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations 2015 pertaining to ESOP 2012 |
Tue, 22 Aug 2023
Announcement under Regulation 30 (LODR)-Allotment Allotment of 4 900 (Four Thousand and Nine Hundred) Rated Listed Unsecured Redeemable Taxable Non-Convertible Debentures of Nominal value of Rs.1 00 000/-(Rupees One Lakh Only) each aggregating to Rs.49 00 00 000/-(Rupees Forty Nine Crore Only) on private placement basis by Astec LifeSciences Limited. |
Mon, 14 Aug 2023
Intimation / Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Pendency Of Litigation(S) Or Dispute(S) Please find enclosed the disclosure under Regulation 30 of the SEBI Listing Regulations regarding pendency of litigation(s) or dispute(s). |
Mon, 25 Sep 2023 |
|
|
|
|
|